Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.
Acoustic startle response
Depression
GABA
Menstrual cycle
Neuroactive steroid
Premenstrual
Progesterone
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
03
09
2020
accepted:
30
06
2021
pubmed:
23
7
2021
medline:
16
10
2021
entrez:
22
7
2021
Statut:
ppublish
Résumé
Women with premenstrual dysphoric disorder (PMDD) appear to have altered central nervous system sensitivity to neuroactive steroid hormones, manifesting as affective symptoms and heightened arousal in the luteal phase of the menstrual cycle. In particular, women with PMDD appear less sensitive to allopregnanolone, a positive allosteric GABA-A receptor (GABA-A-R) modulator. This study evaluated psychophysiologic reactivity in women with PMDD in the follicular and luteal phases of the menstrual cycle, utilizing anxiety-potentiated startle (APS), a potential translational marker of GABA-A-R sensitivity. The study also assessed APS response to low-dose sertraline treatment in women with PMDD. Participants' APS and fear-potentiated startle (FPS) were assessed in the follicular and luteal phases. Women with PMDD received 50 mg sertraline in the following luteal phase to examine impact on APS and FPS. There were no significant differences between controls (n = 41) and PMDD participants (n = 36) in change from follicular to luteal phases in baseline startle, APS nor FPS. However, among participants who responded to sertraline, APS was higher in the untreated luteal phase than the follicular phase, but lower in the treated luteal phase than the follicular phase. These data demonstrate elevated psychophysiologic arousal in the luteal phase among some women with PMDD, suggesting impaired ability to modulate arousal reactivity. Specifically, alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders.
Identifiants
pubmed: 34292344
doi: 10.1007/s00213-021-05916-6
pii: 10.1007/s00213-021-05916-6
doi:
Substances chimiques
Sertraline
QUC7NX6WMB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2985-2997Subventions
Organisme : NIMH NIH HHS
ID : K23 MH107831
Pays : United States
Organisme : Brain and Behavior Research Foundation
ID : Young Investigator Award
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alvarez RP, Chen G, Bodurka J et al (2011) Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage 55:389–400. https://doi.org/10.1016/j.neuroimage.2010.11.057
doi: 10.1016/j.neuroimage.2010.11.057
pubmed: 21111828
American Psychiatric Assn A (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
doi: 10.1176/appi.books.9780890425596
Bäckström T, Haage D, Löfgren M et al (2011) Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191:46–54. https://doi.org/10.1016/j.neuroscience.2011.03.061
doi: 10.1016/j.neuroscience.2011.03.061
pubmed: 21600269
Bäckström T, Bixo M, Nyberg S, Savic I (2013) Increased neurosteroid sensitivity–an explanation to symptoms associated with chronic work related stress in women? Psychoneuroendocrinology 38:1078–1089. https://doi.org/10.1016/j.psyneuen.2012.10.014
doi: 10.1016/j.psyneuen.2012.10.014
pubmed: 23177572
Bäckström T, Bixo M, Johansson M et al (2014) Allopregnanolone and mood disorders. Prog Neurobiol 113:88–94. https://doi.org/10.1016/j.pneurobio.2013.07.005
doi: 10.1016/j.pneurobio.2013.07.005
pubmed: 23978486
Bengtsson SKS, Nyberg S, Hedström H et al (2015) Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology 52:22–31. https://doi.org/10.1016/j.psyneuen.2014.10.025
doi: 10.1016/j.psyneuen.2014.10.025
pubmed: 25459890
Bixo M, Ekberg K, Poromaa IS et al (2017) Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-a randomized controlled trial. Psychoneuroendocrinology 80:46–55. https://doi.org/10.1016/j.psyneuen.2017.02.031
doi: 10.1016/j.psyneuen.2017.02.031
pubmed: 28319848
Bixo M, Johansson M, Timby E et al (2018) Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol 30. https://doi.org/10.1111/jne.12553
Davis M, Walker DL, Miles L, Grillon C (2010) Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35:105–135. https://doi.org/10.1038/npp.2009.109
doi: 10.1038/npp.2009.109
pubmed: 19693004
Devall AJ, Santos JM, Fry JP et al (2015) Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats. Eur Neuropsychopharmacol 25:113–123. https://doi.org/10.1016/j.euroneuro.2014.11.017
doi: 10.1016/j.euroneuro.2014.11.017
pubmed: 25498416
Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM et al (2017) Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry 174:51–59. https://doi.org/10.1176/appi.ajp.2016.15121510
doi: 10.1176/appi.ajp.2016.15121510
pubmed: 27523500
Endicott J, Nee J, Harrison W (2006) Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 9:41–49. https://doi.org/10.1007/s00737-005-0103-y
doi: 10.1007/s00737-005-0103-y
pubmed: 16172836
Epperson C, Pittman B, Czarkowski KA et al (2007) Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 32:2190–2198. https://doi.org/10.1038/sj.npp.1301351
doi: 10.1038/sj.npp.1301351
pubmed: 17314917
Epperson CN, Steiner M, Hartlage SA et al (2012) Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 169:465–475
doi: 10.1176/appi.ajp.2012.11081302
Eriksson E, Ekman A, Sinclair S et al (2008) Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28:195–202. https://doi.org/10.1097/JCP.0b013e3181678a28
doi: 10.1097/JCP.0b013e3181678a28
pubmed: 18344730
Evans SM, Foltin RW, Fischman MW (1999) Food “cravings” and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 32:331–349. https://doi.org/10.1006/appe.1998.0222
doi: 10.1006/appe.1998.0222
pubmed: 10336792
Freeman EW, Jabara S, Sondheimer SJ, Auletto R (2002) Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 11:459–464. https://doi.org/10.1089/15246090260137635
doi: 10.1089/15246090260137635
pubmed: 12165163
Freeman EW, Halbreich U, Grubb GS et al (2012) An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85:437–445. https://doi.org/10.1016/j.contraception.2011.09.010
doi: 10.1016/j.contraception.2011.09.010
pubmed: 22152588
Gehlert S, Song IH, Chang C-H, Hartlage SA (2009) The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med 39:129–136. https://doi.org/10.1017/S003329170800322X
doi: 10.1017/S003329170800322X
pubmed: 18366818
Gracia CR, Freeman EW, Sammel MD et al (2009) Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol 29:403–405. https://doi.org/10.1097/JCP.0b013e3181ad8825
doi: 10.1097/JCP.0b013e3181ad8825
pubmed: 19593190
Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 96:13512–13517
doi: 10.1073/pnas.96.23.13512
Grillon C, Chavis C, Covington MF, Pine DS (2009) Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study. Neuropsychopharmacology 34:964–971. https://doi.org/10.1038/npp.2008.141
doi: 10.1038/npp.2008.141
pubmed: 18800069
Halbreich U (2008) Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 13:566–572
doi: 10.1017/S1092852900016849
Halbreich U, O’Brien PMS, Eriksson E et al (2006) Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs 20:523–547
doi: 10.2165/00023210-200620070-00001
Hantsoo L, Epperson CN (2015) Premenstrual dysphoric disorder: epidemiology and treatment. Curr Psychiatry Rep 17:87. https://doi.org/10.1007/s11920-015-0628-3
doi: 10.1007/s11920-015-0628-3
pubmed: 26377947
pmcid: 4890701
Hantsoo L, Epperson CN (2020) Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress 12:100213. https://doi.org/10.1016/j.ynstr.2020.100213
doi: 10.1016/j.ynstr.2020.100213
pubmed: 32435664
pmcid: 7231988
Hantsoo L, Golden CEM, Kornfield S et al (2018) Startling differences: using the acoustic startle response to study sex differences and neurosteroids in affective disorders. Curr Psychiatry Rep 20:40. https://doi.org/10.1007/s11920-018-0906-y
doi: 10.1007/s11920-018-0906-y
pubmed: 29777410
pmcid: 6050032
Hedström H, Bäckström T, Bixo M et al (2015) Women with polycystic ovary syndrome have elevated serum concentrations of and altered GABAA receptor sensitivity to allopregnanolone. Clin Endocrinol (oxf). https://doi.org/10.1111/cen.12809
doi: 10.1111/cen.12809
Klatzkin RR, Lindgren ME, Forneris CA, Girdler SS (2010) Histories of major depression and premenstrual dysphoric disorder: evidence for phenotypic differences. Biol Psychol 84:235–247. https://doi.org/10.1016/j.biopsycho.2010.01.018
doi: 10.1016/j.biopsycho.2010.01.018
pubmed: 20138113
pmcid: 2877489
Kornstein SG, Pearlstein TB, Fayyad R et al (2006) Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 67:1624–1632
doi: 10.4088/JCP.v67n1020
Landén M, Nissbrandt H, Allgulander C et al (2007) Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32:153–161. https://doi.org/10.1038/sj.npp.1301216
doi: 10.1038/sj.npp.1301216
pubmed: 17035933
Lovick T (2013) SSRIs and the female brain–potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias. J Psychopharmacol Oxf Engl 27:1180–1185. https://doi.org/10.1177/0269881113490327
doi: 10.1177/0269881113490327
McEvoy K, Osborne LM (2019) Allopregnanolone and reproductive psychiatry: an overview. Int Rev Psychiatry Abingdon Engl 31:237–244. https://doi.org/10.1080/09540261.2018.1553775
doi: 10.1080/09540261.2018.1553775
Meltzer-Brody S, Colquhoun H, Riesenberg R et al (2018) Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Lond Engl 392:1058–1070. https://doi.org/10.1016/S0140-6736(18)31551-4
doi: 10.1016/S0140-6736(18)31551-4
Möller AT, Bäckström T, Nyberg S et al (2016) Women with PTSD have a changed sensitivity to GABA-A receptor active substances. Psychopharmacology 233:2025–2033. https://doi.org/10.1007/s00213-014-3776-y
doi: 10.1007/s00213-014-3776-y
pubmed: 25345735
Nagaya N, Acca GM, Maren S (2015) Allopregnanolone in the bed nucleus of the stria terminalis modulates contextual fear in rats. Front Behav Neurosci 9:205. https://doi.org/10.3389/fnbeh.2015.00205
doi: 10.3389/fnbeh.2015.00205
pubmed: 26300750
pmcid: 4523814
Nelson M, Pinna G (2011) S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology 60:1154–1159. https://doi.org/10.1016/j.neuropharm.2010.10.011
doi: 10.1016/j.neuropharm.2010.10.011
pubmed: 20971127
Nguyen TV, Reuter JM, Gaikwad NW et al (2017) The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback. Transl Psychiatry 7:e1193. https://doi.org/10.1038/tp.2017.146
doi: 10.1038/tp.2017.146
pubmed: 28786978
pmcid: 5611719
Pearlstein T, Steiner M (2008) Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci JPN 33:291–301
pubmed: 18592027
Pincus SM, Alam S, Rubinow DR et al (2011) Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res 45:386–394. https://doi.org/10.1016/j.jpsychires.2010.07.006
doi: 10.1016/j.jpsychires.2010.07.006
pubmed: 20708199
Pinna G, Costa E, Guidotti A (2009) SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 9:24–30. https://doi.org/10.1016/j.coph.2008.12.006
doi: 10.1016/j.coph.2008.12.006
pubmed: 19157982
pmcid: 2670606
Robinson SM, Sobell LC, Sobell MB, Leo GI (2014) Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav 28:154–162. https://doi.org/10.1037/a0030992
doi: 10.1037/a0030992
pubmed: 23276315
Schmidt PJ, Martinez PE, Nieman LK et al (2017) Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry 174:980–989. https://doi.org/10.1176/appi.ajp.2017.16101113
doi: 10.1176/appi.ajp.2017.16101113
pubmed: 28427285
pmcid: 5624833
Schmitz A, Grillon C (2012) Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc 7:527–532. https://doi.org/10.1038/nprot.2012.001
doi: 10.1038/nprot.2012.001
pubmed: 22362158
pmcid: 3446242
Sobell LC, Sobell MB (1992) Timeline Follow-Back. In: Litten RZ, Allen JP (eds) Measuring alcohol consumption: psychosocial and biochemical methods. Humana Press, Totowa, pp 41–72
doi: 10.1007/978-1-4612-0357-5_3
Steinberg EM, Cardoso GMP, Martinez PE et al (2012) Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depress Anxiety 29:531–540. https://doi.org/10.1002/da.21959
doi: 10.1002/da.21959
pubmed: 22565858
pmcid: 3442940
Steiner M, Ravindran AV, LeMelledo J-M et al (2008) Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry 69:991–998
doi: 10.4088/JCP.v69n0616
Sundström Poromaa I, Smith S, Gulinello M (2003) GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 6:23–41. https://doi.org/10.1007/s00737-002-0147-1
doi: 10.1007/s00737-002-0147-1
pubmed: 12715262
Timby E, Bäckström T, Nyberg S et al (2016) Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology. https://doi.org/10.1007/s00213-016-4258-1
doi: 10.1007/s00213-016-4258-1
pubmed: 26960697
Toufexis DJ, Davis C, Hammond A, Davis M (2004) Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone. J Neurosci 24:10280–10287. https://doi.org/10.1523/JNEUROSCI.1386-04.2004
doi: 10.1523/JNEUROSCI.1386-04.2004
pubmed: 15537900
pmcid: 6730196
Uzunova V, Sheline Y, Davis JM et al (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A 95:3239–3244. https://doi.org/10.1073/pnas.95.6.3239
doi: 10.1073/pnas.95.6.3239
pubmed: 9501247
pmcid: 19726
Walker DL, Toufexis DJ, Davis M (2003) Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 463:199–216. https://doi.org/10.1016/S0014-2999(03)01282-2
doi: 10.1016/S0014-2999(03)01282-2
pubmed: 12600711
Yonkers KA, Kornstein SG, Gueorguieva R et al (2015) Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiat 72:1037–1044. https://doi.org/10.1001/jamapsychiatry.2015.1472
doi: 10.1001/jamapsychiatry.2015.1472